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Introduction
In a recent publication [1] Adler et al defined radio-
surgery as ‘precise targeting of cross-fired radiation beams
to abnormal tissues with an abrupt fall-off of radiation
doses to surrounding normal tissues’ and as ‘a procedure
that involves the active participation of a surgeon and in
which spatially accurate and highly conformal doses of
radiation are targeted at well-defined structures with an
ablative intent’. This demonstrates that it is of critical
importance to properly define new treatment strategies
and techniques [2].
Stereotactic radiosurgery is a rapidly emerging fied
within radiation oncology which is expanding from the
initial limitation of only cranial radiotherapy to
encompass extracranial radiotherapy applications. The
early restrictions to its use for was due to factors such as
the requirement for a non-mobile target, and a lack of
very precise stereotactic imaging software: e.g. for CT,
MRI and angiography. It was necessary to use only
a limited number of fractions in order to avoid difficult
repeat set-ups which were often invasive. Also, due to
the radiobiology of tumours and normal tissues the
volume and the dose given in a single shot had to be
limited to avoid extensive necrosis of the irradiated
surrounding normal tissues [3, 4].
Expanding applications from cranial to extracranial
malignant and non-malignant conditions presents requires
a solution to the problem of how to deal with mobile
organs and what restrictions are necessary. The new
developments of imaging technology such as in SPECT,
MRI and PET, provides more useful information for the
definition of the target volume and surrounding normal
tissues. The ultimate tool would be to track the tumour in
real time.
The limitation for treatment planning and delivery is
the complexity of the precision process. With the Cyber-
Knife being a frameless system, unlike the Gamma Knife
where a head frame is essential, this opens up a wide
range of current and future possibilites for extracranial
stereotactic radiosurgery. Although it must be realised
that the more complex the overall systems the longer it
will take to define the target, set up the patient and
deliver treatment. This implies that there is no alternative
other than decreasing the total number of fractions [5].
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Changing from a single shot with a low dose to
a limited volume in order to obtain necrosis of normal
tissues (e.g. arteriovenous malformations) to multiple
shots (fractionation) with a curative total dose to a large
volume (i.e. tumours and their margins which form the
CTV) to obtain tumour cure and a protection of
surrounding normal tissues will need extremely precise
techniques and machines as well as a compromise on the
number of fractions to be delivered [5]. This compromise
must not be compared to that chosen for medico-
economical reasons. In other word, decrease the total
number of fractions delivered in order to potentially
increase the number of treated patients and hence
improve the cost implications.
Extracranial stereotactic radiosurgery
To properly extend stereotactic radiotherapy from cranial
to extracranial sites requires extremely precise tools and
a frameless system such as that of the CyberKnife.
Practice guidelines for stereotactic body radiation therapy
were published in 2004 by the American Society for
Therapeutic Radiology and Oncology and the American
College of Radiology [6].
The conclusion by ASTRO and ACR was as follows.
‘The quality of the stereotactic body radiation therapy
[SBRT] program is only as good as it’s weakest link. High
spatial accuracies are expected and time constraints are
relatively short. Since SBRT uses either single fraction
treatment or a hypofractionated regimen, there is little
chance for adjustment once treatment has been initiated.
This demands considerable time for planning and
treatment verification by the radiation oncologist and
medical physicist’.
Hypofractionated regimens have been widely used in
palliative settings such as for treatment of bone meta-
stases in order to rapidly relieve pain by quickly obtaining
anti-tumour and anti-oedema effects. In some metastatic
diseases such as those of liver and lung, a long-term
tumour response can be obtained by delivering a high
biological effective dose (BED) in the short-term. This
limits the constraints for the patients, even if their mean
survival remains short.
Hypofractionated regimens can only be considered
as a sole curative treatment if precise definition and
tracking of the target is obtained [7]. Furthermore,
a biological rationale must exist in order to consider
implementing the technique in patients.
For prostate cancer, there is currently a debate on
hypofractionated treatment [8]. The target is well defined
using MRI, the α/β ratio may be low in most of the
tumours and the tracking can be obtained. However, the
rectal mucosa is very close to the surface of the prostate,
< 5 mm, and some morbidity can be expected. For
prostate cancer, CyberKnife treatment has been simulated
with inverse planning, using non-coplanar non-isocentric
arcs and compared to IMRT delivered with a linear
accelerator [9]. Conformal isodose curves and dose-
volume histograms have been drawn with superior DVHs
obtained with the Cyberknife with regard to sparing of
normal tissues. Preliminary clinical experiences have also
been published and for spinal lesions, a regimen of 11-25
Gy in 1-5 fractions has been used with good results at six
months follow-up [10].
Finally, it is noted that a single high dose can be
delivered as a boost before or after fractionated
treatment. This has been performed in intraoperative
radiotherapy and as a boost for brain and for some
gynaecological tumours. Currently, we are now close to
what is achieved by a HDR brachytherapy boost after
external beam treatment.
For brain tumour metastases, the recently published
RTOG 95087 study demonstrated that there was a benefit
in terms of survival for patients with a single unresectable
metastasis, when delivering a stereotactic radiosurgery
boost after whole brain irradiation: from 24 Gy in 2 cm
diameter to 15 Gy in 4 cm diameter lesions [11], Tables I
and II. However the risk of tissue necrosis remains high
and limits the hypofractionation used and the normal
tissue volumes irradiated [7]
Table I. Causes of death from the RTOG 9508 study [11]. 
WBRT = whole brain radiation therapy
Cause of death WBRT & stereotactic WBRT alone
N = 137 N = 149
Brain metastases 39 (28%) 46 (31%)
Cancer: other site 69 (50%) 80 (54%)
Radiotherapy complications 1 (1%) 0 (0%)
Unknown 12 (9%) 8 (5%)
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Table II. Multivariate survival analysis for the RTOG 9508 study [11].
RPA classes = recursive partitioning analysis classes for brain metastases
Number of cases Mean survival time (months) P-value Association with a better prognosis
The overall study 327
RPA class 1 versus class 2 2.254 < 0.0001 Class 1
Histology 1.348 0.0121 Lung primary
WBRT versus WBRT + stereotactic not known 0.1249 Not significant
Single metastasis 184
RPA class 1 versus class 2 2.897 < 0.0001 Class 1
WBRT versus WBRT + stereotactic not known 0.0533 Not significant
Hypoxia and radiation therapy
The biological effectiveness of low LET ionising radiation
is mostly due to the oxygen present at the time of
treatment in the cell environment [12, 13]. Oxygen
availability depends on oxygen supply and tissue oxy-
genation will result directly from O2 availability and from
the respiration rate of the cells. In tumours, tissue
vascularisation is qualitatively poor with shunts, collapsed
vessels and high interstitial pressure [14, 15]. Hypoxic
cells are present in rodent and xenografted human
tumours and it has been known for a long time that the
absence of oxygen in tumours is a factor of resistance
against ionising radiation [16-18]. The low tumour oxygen
tension could also be a factor of resistance for treatment
with some cytotoxic drugs [19].
P h y s i o l o g y  o f  h y p o x i a
In mammalian cells, most of the energy for cellular life
arises from oxidation and reduction reactions with ATP
synthesis [20]. Large variations in the density of vessels
have been demonstrated during tumour growth and
hypoxia is present not only in large tumours with necrosis,
but also in small tumours [21, 22]. This is related in part to
the growth site, tumour cell density and to variations in
vascularisation [23]. The oxygen supply for a defined
tumour at a precise time and at a specific point will
depend on the tumour blood flow at that time. Cell killing
by ionising radiation occurs through DNA damage. For
low LET radiations the most frequent targets are water
molecules, which become converted to free radicals
leading to DNA damage.
The oxygen enhancement ratio (OER) under
oxygenation conditions versus anoxic conditions has
a range of 2.5-3.5 for X-rays, gamma rays and electrons
[13]. However, for heavy ions and neutrons, the radiation
effects are much less dependent on free radicals and have
a much lower OER which is close to 1.0. Although the
effects of hypoxia on radioresistance have been well
characterised, there are other tumour characteristics
which have an influence on the curability of tumours.
For example there is the biological response to
hypoxia and at the genetic transcription level, several
genes have been shown to be regulated by hypoxic stimuli
[24, 25]. A hypoxia inducible transcription factor (HIF-1)
which was initially identified as the specific transcription
factor involved in the control of the erythropoietin gene,
is now known to regulate multiple cellular processes such
as the expression of vascular endothelial growth factor
(VEGF) [26, 27]. In addition to the HIF-1 response which
is specific to hypoxia, other less specific responses also
occur as a result of hypoxic stress including p53, AP-1,
NF-kB, SP-1 and the proto-oncogenes Jun and Fos. These
diverse effects on gene transcription are consistent with
the ubiquitous and fundamental effects of hypoxia on
cellular metabolism [28-32].
S t u d i e s  o f  o x y g e n  p a r t i a l  p r e s s u r e  i n
t u m o u r s
Hypoxia is present to a significant degree in solid tumours
[20]. The blood vessels do not carry blood as efficiently as
normal vessels and are not under regulatory control and
tumours typically contain normoxic, hypoxic and necrotic
regions [23]. In 1956 Thomlinson and Gray constructed
their model of tumour oxygenation with cords of
oxygenated cells surrounding each capillary [22]. Tissues
can maintain full oxygenation if they are within 100 µm of
a perfused capillary. However, at distances between
100 µm and 150 µm, the tissues are chronically hypoxic.
Beyond 150 µm the tissues are anoxic and necrotic.
It has since become apparent that the situation in
tumours is far more complex due to the unorganised
nature of tumour vasculature. Most of the oxygen in
normal tissues is distributed via arterioles and tumour
capillaries are inadequate since blood is carried by these
vessels. Changes in the perfusion and/or oxygenation of
many tumour cells is not only dependent on location
within the tumour but varies over time by as much as 10-
fold [32, 33].
A n g i o g e n e s i s  a n d  l o s s  o f  c e l l  a d h e s i o n
Angiogenesis is the formation of new blood vessels.
However, hypoxia is also an important phenomenon in
tumour development. If a tumour cannot induce the
formation of new vascular connections with the adjacent
blood vessels, it is unable to grow beyond the size limits
imposed by oxygen diffusion: a diameter of < 1 mm).
For this reason, an angiogenic phenotype appears to be
essential for development of a malignant tumour [27, 32].
A principal positive regulator of angiogenesis in normal
tissues is VEGF which is under control of HIF-1. Also,
angiogenesis is highly responsive to hypoxia in normal
tissues or in tumours [34]. The resulting vascularisation
not only promotes growth but also increases the potential
for metastatic spread because of improved access of
malignant cells to the bloodstream.
G e n e t i c  i n s t a b i l i t y  a n d  s e l e c t i o n  o f
m a l i g n a n t  p h e n o t y p e
Hypoxia itself may promote increased genetic instability
[35]. Experimental studies have shown an increase in
metastatic potential linked specifically with reoxygenation
following hypoxia. This reoxygenation stage induces cell
cycle perturbations and DNA overreplication. The
selection pressure exerted by hypoxia may also favour
other characteristics that produce a more malignant
phenotype [36]. One example is loss of functional p53
which is the most frequently mutated gene in tumours.
It suggests the hypothesis that its function is to
protect the organism by preventing the replication of cells
with damaged or mutant DNA. In normal cells, hypoxia
can induce p53 mediated apoptosis. In addition, a hypoxic
environment applies a selection pressure favouring, in
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any genetically unstable tumour lineage, the survival of
cells with mutant p53. This selection has been
demonstrated in oncogenically transformed tissue culture
cells [30].
Te c h n i q u e s  o f  o x y g e n  t e n s i o n
m e a s u r e m e n t s
Methods for measuring the oxygen present in tissues can
be divided into invasive and non-invasive techniques. The
ideal method for measurement would need to be accurate
and reproducible, to have a good spatial resolution,
a sensitivity in the clinically relevant range and to be user
friendly and safe. For clinical usefulness, a non-invasive
method should be preferred but most of the available
techniques give only an indirect estimation of oxygen
pressure in the tissue assessed [37].
For the polarographic technique, an electrical
current is generated between a cathode (probe) and an
anode. The variations in oxygen concentration in the
tissue will induce oxidation of the electrode, leading to
modifications in the current which is proportional to pO2.
The electrode must have a minimal oxygen consumption,
should avoid tissue compression, have a fast response,
be easily calibrated with minimal drift and specific of
oxygen. The exact volume of oxygen detection in tissues
by modern probes corresponds to the micro-environment
of the tumour cells.
The principle of hypoxia markers is based on the
fact that the binding of hypoxic cells radiosensitisers,
as for example 2-nitroimidazole, to tumour cells is
dependent on oxygen concentration [38, 39]. The limi-
tation of these techniques is due to the uncertainty in the
bio-distribution of the marker due to variations in tumour
blood flow and on the exact correlation between the
intensity of the binding and the partial oxygen pressure in
the tissue. This means that the measure will serve more
on an individual monitoring of oxygen distribution in
time, than on a comparison between different tumours.
The binding can be detected by invasive techniques
such as biopsy or immunochemical; or by non-invasive
techniques such as PET or MRI. Hypoxia is detected at
a cellular level with the invasive techniques (biopsy or
needle) and can be associated with the evaluation of other
parameters (proliferation). For non-invasive techniques,
the micro-environment is by definition not modified by
the sampling, but the recording corresponds more to an
evaluation of tissues than of cells.
In a National Institutes of Health consensus
workshop held in November 1992, the various advantages
and disadvantages of such techniques were reviewed [40].
For measuring tissue oxygenation it was concluded that
a comparison of techniques would be advisable with
oxygen electrodes serving as the ‘gold standard’. The
different techniques used for measuring oxygen tension in
tumours might give different information than infor-
mation on ‘biologically significant’ tumour hypoxia.
p O2 d i s t r i b u t i o n  i n  t u m o u r s
Oxygen tension has been measured in head and neck,
cervix, brain tumours, melanoma and sarcomas [41-47]. In
metastatic neck nodes from a primary squamous cell
carcinoma of the head and neck (cancer of the oro-
pharynx in 31/35 patients) pO2 measurements were
performed immediately before treatment (surgery or
radiotherapy) [41]. The median pO2 was 9 mmHg with
a mean pO2 of 21 mmHg. Low pO2 values of <10 mmHg
were found in 83 % of the tumours. The tumour-to-
tumour proportion of very low values of <2 mmHg varied
widely in the range 2.5-100%.
Tumour pO2 values generally varied along the
electrode tracks but in general, there appeared to be no
systematic variation in pO2 as a function of the electrode
position in the tumour. That is, no decrease in pO2 from
the superficial to the deep part of the tumour. The pO2
distribution did not differ according to the age of the
patient or to the histological grade of the tumour.
The distribution of oxygen tension varied greatly
from one tumour to another, indicating differences in
tumour oxygenation between patients with the same
histological tumours: inter-tumor variability. Recently,
pO2 measurements have been performed in prostate
cancer. The median pO2 was in the range 0.2-57.3 mmHg
with a median of 4.5 mmHg. A large intra-tumour
variability was found [42].
Fa c t o r s  i n f l u e n c i n g  p O2 v a r i a t i o n
The factors studied which can possibly influence pO2
variation are (1) tumour size, (2) haemoglobin
concentration, (3) tumour treatment and (4) carbogen
breathing.
With regard to (1) tumour size in head and neck
tumours, a trend has been demonstrated showing
a decrease in the median pO2 (there is an increase in the
frequency of very low values < 2 mmHg) associated with
an increase in tumour size: N2 versus N3, p = 0.012 [41].
The same trend was also found in sarcomas [44]. With
regard to (2) haemoglobin concentration, no correlation
between haemoglobin level and intratumour oxygen
tension distribution was found in all studies except for
one.
With regard to (3) tumour treatment the variations
in tumour oxygenation during very accelerated radiation
therapy for advanced head and neck carcinoma have been
studied. For normal tissues outside the radiation field,
the oxygen distribution was not significantly increased
during treatment. There was a pooled median pO2 of 38
mmHg before treatment which was 46 mmHg after two
weeks of treatment. For tumours, the pooled median pO2
was 13 mmHg before treatment and 33 mmHg after two
weeks of treatment. This difference was significant,
P=0.05. Very low values of <2 mmHg represented 20%
of the recorded values before treatment and 10% after
two weeks. Low pO2 values of <10 mmHg accounted for
respectively 45% and 25% of the recorded values before
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and after treatment [43]. With regard to (4) carbogen
breathing an efficient method to decrease the percentage
of low pO2 values in tumours is to breathe carbogen, or
pure oxygen, throughout every radiotherapy treatment
fraction [45]. Oxygen tension has been recorded in
tumours before and at the time of carbogen breathing.
A decrease in the percentage of very low values of < 2
mmHg was obtained in 9/13 patients.
P r e d i c t i v e  v a l u e  o f  p O2 m e a s u r e m e n t s
The predictive value of pO2 measurements for treatment
response has been demonstrated in cervix and head and
neck tumours and in sarcomas. In 35 patients locally
advanced head and neck tumours, Nordsmark et al
demonstrated that pO2 was a significant and independent
parameter for predicting local tumour control after
treatment exclusively by radiotherapy [46]. Actuarial
tumour control probability at two years was 70% for well
oxygenated tumours, versus 36% for poorly oxygenated
ones, P=0.01. The parameter studied was the fraction of
pO2 values <2.5 mmHg. In an investigation of patients
with soft tissue sarcoma, well oxygenated tumours
(median pO2 >10 mm Hg) were associated with a two-
fold higher probability of disease free survival at 18
months than were those with poorly oxygenated tumours
(median pO2 <10 mm Hg), P<0.01 [47]. It was found
that treatment failure and relapse were due primarily to
distant metastases. It was concluded that tumour hypoxia
was a powerful prognostic factor for metastatic potential.
Finally, it can be said that most of the solid tumours
in man contain areas of hypoxia. The measurement of
tumour pO2 can be considered as a predictive indicator of
treatment response in cervix and head and neck tumours.
Oxygen tension can be modulated by carbogen breathing
and can vary during radiation therapy [48, 49]. Also, even
if tumour hypoxia is a highly relevant parameter for
treatment outcome, the best parameter to demonstrate
predictive tumour hypoxia is still not clearly defined.
Does hypofractionation counteract hypoxia?
Ro l e  o f  f r a c t i o n a t i o n
Repair of sublethal damage, tumour repopulation and
the level of tumour (re-) oxygenation are the main factors
which determine the outcome of any particular irradiation
schedule. Cell cycle redistribution is less important. The
only problem is to understand the range of dose and dose
rates at which the variation in biological effectiveness is of
clinical significance. This depends on two main factors,
repair capacity and repair kinetics, which will change
from tissue to tissue.
The analysis of radiation effects in vivo reveals
important differences between fast and slow proliferating
tissues: that is, early and late effects [3, 4]. These two
groups of tissues of course differ in their latency before
reacting to an irradiation, but they also differ in their
sensitivity to alterations in the fraction size in
a fractionated irradiation schedule. Variations in the dose
per fraction have an impact on tolerance to radiation
which is comparatively greater in late than in early
reacting tissues or tumours. The skin for instance, which
is a typical acute reacting tissue, is relatively insensitive to
decreasing the dose per fraction beyond about 2-3 Gy.
This difference in fractionation sensitivity is interpreted as
reflecting differences in sublethal damage repair capacity
and constitutes the basis of the differential effect of
fractionation on early and late responding tissues.
In changing the fractionation, one would have
considered calculating an isoeffect dose. However, it must
be stated that the α/β linear-quadratic (LQ) model is
only valid for fractionated treatment in the range 2-20 Gy
per fraction with uncertainties on α/β and on T1/2 Most of
the calculations are made with the LQ model assuming
mono-exponential repair kinetics rather than multi-
exponential.
In summary, any increase in dose per fraction (or
in dose rate) will have a greater biological impact on slow
responding normal tissues than on tumours. To expect
any increase in therapeutic ratio, the amount of normal
tissues in the treated volume will have to be as reduced by
as much as possible. This is what can be achieved using
CyberKnife stereotactic radiosurgery, unlike the use of
conventional fractionated radiation therapy.
Hypofractionation in clinical practice
Using large doses per fraction for curative tratment is
still considered to be a challenge. A recent paper by
Fowler et al studied the comparison of a 2 Gy equivalent
dose with large fraction doses [3]. A new concept was
developed: the prescription isodose volume PIV, for
comparison with the planning treatment volume PTV in
models of large fraction doses in lung carcinoma.
A regimen of 35 x 2 Gy was compared to 3 x 15 Gy or 4 x
12 Gy (>110 Gyα/β10) used in stereotactic hypofractio-
nated schemes.
If in a tumour with 1010 resistant cells reoxygention is
incomplete with 1% remaining hypoxic cells, then 8 log
cells will remain hypoxic and the total biological dose
will have to be at least three times higher to control the
tumour. If OER is only 2.5 and not 3, then fractions of
3 x 23 Gy will be necessary and not 3 x 15 Gy. However,
this must be placed in perspective with the evaluated
number of patients having hypoxic tumours. This is an
evaluation which is still difficult clinically. Furthermore,
hypoxia remains only one of the potential factors affecting
radioresistance. Also, the number of critical factors (such
as repopulation, cell kinetics, proliferation and
oxygenation) may vary during the course of a fractionated
radiotherapy regimen [50].
Finally these biological concepts must be seen in the
perspective of treated volumes. If the minimum PIV is
considered, a PTV of 5 cm in diameter will be decreased
to 4 cm in diameter by a reduction in the margin of 0.5 cm
(i.e. a 20% decrease) but the volume will be halved
(65.5 cm3 to 33.5 cm3).
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Conclusions
It is logical to consider increasing the dose per
fraction in stereotactic radiosurgery where the target can
be precisely located and the irradiated volume can be
limited. However, only long-term clinical evaluation will
allow a generalisation of the concept in curative treatment
for the most commonly treated human tumours. Fully
integrated robotic radiosurgery systems such as the
CyberKnife may allow us to achieve this goal [51].
Eric Lartigau MD, PhD
Radiotherapy Department
Centre Oscar Lambret and University Lille II
3 rue F. Combemale
59000 Lille, France
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